Navigation Links
InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
Date:9/4/2007

- Phase 1b trial expected to begin in September -

BRISBANE, Calif., Sept. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the amended Clinical Trial Authorization (CTA) related to the Phase 1b clinical trial of ITMN-191 (Roche-R7227) has been approved by the appropriate European regulatory authorities. InterMune also has received approval from the Ethics Committee of the institutions that will conduct the Phase 1b study. ITMN-191 is an orally available hepatitis C virus (HCV) protease inhibitor in development by InterMune and its partner, Roche.

InterMune expects that the Phase 1b multiple ascending dose (MAD) study will begin this month and expects to announce initial top-line viral kinetic and safety results from the first three dose cohorts of the MAD study in the first quarter of 2008.

Dan Welch, President and Chief Executive Officer of InterMune, said, "InterMune and Roche are pleased to announce that we have successfully secured the required regulatory approvals that enable us to initiate our very important Phase 1b multiple ascending dose study. By amending the Phase 1b protocol, we believe we have enhanced our ability to deliver the most robust Phase 1b results possible which we expect will place us in a stronger position to begin our Phase 2 trials."

In early May, InterMune announced that it would amend the CTA to take into consideration new information on competitive protease inhibitors, in-vitro and preclinical data on ITMN-191 and pharmacokinetic observations from a Phase 1a study that was completed in May of 2007. In that study, a higher than anticipated exposure of ITMN-191 in plasma was observed in subjects dosed with food, suggesting tha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Mich. , July 29, 2015  Medical Care ... systems for seniors, today announced availability of its new ... system . Worn around the neck or on the ... from anywhere in the USA ... ELITE represents the next generation in mobile and automatic ...
(Date:7/29/2015)... India , July 29, 2015 TAKE Solutions ... foray into the big data market for the Life Sciences ... US-based subsidiary, with an initial investment of 3 million ... healthcare and life sciences market (according to projections by McKinsey) ... and advanced analytics. ...
(Date:7/29/2015)... , July 29, 2015 Cogentix Medical, Inc. ... serving the urology market, will release financial results for the ... 2015, after the market close on Monday, August 10, 2015. ... and webcast to discuss these results on Monday, August 10, ... Rob Kill , President and Chief Executive Officer, and ...
Breaking Medicine Technology:New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 2New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 3New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 4TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 2TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 3Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2
... , THOUSAND OAKS, Calif., Aug. 25 ... a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with ... (the T rial to R educe Cardiovascular E ... of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of ...
... , , PALO ALTO, ... today that the company has successfully completed its multicenter validation study ... quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients ... the study by the end of 2009, and will publish the ...
Cached Medicine Technology:Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 2Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 3Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 6Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 7Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 8CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease 2CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease 3CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease 4
(Date:7/29/2015)... CA (PRWEB) , ... July 29, 2015 , ... We are privileged to announce that ... Medicine of USC as the ninth best ophthalmology hospital in the nation for 2015-2016. This ... 10 American hospitals for ophthalmology. , “It is an honor to be included in ...
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired by a successful ... Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative medicine expert in ... financial need. , “We are thrilled for this opportunity to offer prolotherapy treatments ...
(Date:7/29/2015)... ... July 29, 2015 , ... Stealth ... a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, ... options, offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally ...
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran ... Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling ... website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate ...
(Date:7/29/2015)... ... July 29, 2015 , ... The Woodlands and Spring ... lifestyles while donating to worthy charitable causes each month. The new system will track ... camp. For each Check In at each facility, the boot camps will donate 20 ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... your keys has its down sideSAN FRANCISCO, March 13 ... (Medical Sciences) indicate that convincing older drivers to give up ... study of 660 adults aged 63 to 97 showed that ... likely to die over a three-year period than their counterparts ...
... - The Boston Center for Refugee Health and ... treated many of the large number of Tibetan ... individuals arrived in Boston suffering from symptoms of ... monks were diagnosed by their traditional healers as ...
... - Haemacure Corporation (TSX : HAE) released today ... 31, 2009.ResultsRevenues amounted to $19,226, as compared to ... were exclusively derived from the sale of legacy ... $2.7 million, up from $1.2 million for the ...
... half of Americans know that the "better" fats (monounsaturated ... disease, according to a recent survey by the American ... at: http://inr.mediaseed.tv/aha_36307/ "Heart disease remains the No. ... lot about the ,bad, fats lately and what not ...
... occurred in ICUs , , THURSDAY, March 12 (HealthDay News) ... problem in intensive care units, a new study reveals. ... ICUs in 27 countries over a 24-hour period in ... included in the study. , Dr. Andreas Valentin of ...
... MESSA,s East Lansing-based ... consecutive year for superior efficiency and performance in providing ... providing efficient and effective customer service as measured against ... at Purdue University and BenchmarkPortal. "MESSA is ...
Cached Medicine News:Health News:Drive or Die 2Health News:Drive or Die 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 2Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 3Health News:VIDEO From Medialink and the American Heart Association: 'Better Fats' Benefit Heart Health 2Health News:Injected Medication Errors a Major Problem 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3
... HmX offers three-dimensional ... sensitivity, specificity and efficiency ... and reticulocyte analysis. With ... and dependability, HmX is ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
Medicine Products: